{"id":"W1558355135","doi":"10.1002/cncr.28010","title":"Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial","year":2013,"lang":"en","type":"article","venue":"Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Cambridge Memorial Hospital","funders":"National Cancer Institute; Sanofi; Celgene; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Discontinuation; Oncology; Hazard ratio; Clinical endpoint; Randomized controlled trial; Aromatase inhibitor; Cancer; Gynecology; Confidence interval; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009022833,0.0005987433,0.004261708,0.000215,0.00008904003,0.00001672879,0.0002883443,0.0001633585,0.0006801174],"category_scores_gemma":[0.0002507436,0.0003277659,0.0002946204,0.0007984798,0.0007695784,0.000318853,0.00003102625,0.0004531475,0.000002945317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001050697,"about_ca_system_score_gemma":0.002097248,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009899464,"about_ca_topic_score_gemma":0.001275515,"domain_scores_codex":[0.9948435,0.0007858044,0.001959938,0.0006032384,0.001101468,0.000706083],"domain_scores_gemma":[0.9949683,0.001005358,0.002015576,0.0007468846,0.0009558858,0.0003080243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9749988,0.0008079759,0.002267929,0.0002862708,0.001342552,0.00000810393,0.001768348,0.002173226,0.0001153797,0.00004886543,0.00006404693,0.01611856],"study_design_scores_gemma":[0.980668,0.002517447,0.01351114,0.0008200576,0.0005086347,0.000007391543,0.0009953533,0.0004430363,0.00006903765,0.00001857325,0.00008447492,0.0003568422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756876,0.007118377,0.0001555654,0.001910313,0.0003294582,0.0141641,0.0003590973,0.00006433075,0.0002111512],"genre_scores_gemma":[0.9931617,0.0007479032,0.0002078361,0.0004826764,0.0001210863,0.00488855,0.00009903063,0.00008871853,0.0002025334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01747406,"threshold_uncertainty_score":0.9999174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02037856840053433,"score_gpt":0.3230547976171125,"score_spread":0.3026762292165782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}